Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial

American Journal of Epidemiology

Volumn 171, Issue 5, 2010, Pages 571-582

  Schenk, Jeannette M ^a,b   Kristal, Alan R ^a,b   Neuhouser, Marian L ^a,b   Tangen, Catherine M ^a   White, Emily ^a,b   Lin, Daniel W ^a,c   Kratz, Mario ^a,b   Thompson, Ian M ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Inflammation; Obesity; Prostatic hyperplasia

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

AGE STRUCTURE; BASELINE SURVEY; BIOMARKER; BODY MASS; CANCER; HEALTH RISK; OBESITY; PROTEIN; SERUM; SYMPTOM; TEMPORAL ANALYSIS;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTHRITIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; GROUPS BY AGE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RACE; RISK ASSESSMENT; SCORING SYSTEM; SMOKING; WAIST HIP RATIO;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77249147858     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp406     Document Type: Article

References (46)

1. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology. 2000;56(5 suppl 1):3-6.
2. Platz EA, Smit E, Curhan GC, et al. Prevalence of and racial/ ethnic variation in lower urinary tract symptoms and non-cancer prostate surgery in U.S. men. Urology. 2002;59(6): 877-883.
3. Bosch JL, Hop WC, Kirkels WJ, et al. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology. 1995; 46(3 suppl A):34-40.
4. Foster CS. Pathology of benign prostatic hyperplasia. Prostate. 2000;45(suppl 9):4-14.
5. Garraway WM, Kirby RS. Benign prostatic hyperplasia: effects on quality of life and impact on treatment decisions. Urology. 1994;44(5):629-636.
6. Kortt MA, Bootman JL. The economics of benign prostatic hyperplasia treatment: a literature review. Clin Ther. 1996;18(6): 1227-1241.
7. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med. 1995;155(5): 477-481.
8. Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43(2):164-175.
9. Nickel JC, Downey J, Young I, et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999;84(9):976-981.
10. Roehrborn CG, Kaplan SA, Noble WD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study [abstract]. J Urol. 2005;173(suppl 4):346.
11. Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54(6):1379-1384.
12. Mishra VC, Allen DJ, Nicolaou C, et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int. 2007;100(2): 327-331.
13. Kessler OJ, Keisari Y, Servadio C, et al. Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J Urol. 1998;159(3):1049-1053.
14. Kramer G, Steiner GE, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyper-plastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate. 2002;52(1):43-58.
15. Steiner GE, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83(8):1131-1146.
16. Elkahwaji JE, Zhong W, Hopkins WJ, et al. Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis. Prostate. 2007;67(1): 14-21.
17. Kirby RS, Lowe D, Bultitude MI, et al. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol. 1982;54(6):729-731.
18. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4): 256-269.
19. Rivero VE, Motrich RD, Maccioni M, et al. Autoimmune etiology in chronic prostatitis syndrome: an advance in the understanding of this pathology. Crit Rev Immunol. 2007; 27(1):33-46.
20. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3): 347-355.
21. Kristal AR, Arnold KB, Schenk JM, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. J Urol. 2007;177(4):1395- 1400.
22. Giovannucci E, Rimm EB, Chute CG, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140(11): 989-1002.
23. Dahle SE, Chokkalingam AP, Gao YT, et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002;168(2):599-604.
24. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224.
25. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-1557.
26. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2003;24(2):224-243.
27. Neuhouser ML, Schenk J, Song YJ, et al. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the Prostate Cancer Prevention Trial. Prostate. 2008;68(13):1477-1486.
28. Kristal AR, Schenk JM, Song Y, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2008;168(12):1416-1424.
29. Kristal AR, Arnold KB, Schenk JM, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2008;167(8):925-934.
30. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol I. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer; 1980. (IARC scientific publication no. 32).
31. Gerstenbluth RE, Seftel AD, MacLennan GT, et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of BCL-2 in areas of inflammation. J Urol. 2002;167(5):2267-2270.
32. Kefi A, Koseoglu H, Celebi I, et al. Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen. Scand J Urol Nephrol. 2006;40(2):155-160.
33. Feneley MR, Span PN, Schalken JA, et al. A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1999;2(5/6):277-281.
34. Steiner GE, Newman ME, Paikl D, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56(3):171-182.
35. Handisurya A, Steiner GE, Stix U, et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate. 2001;49(4):251-262.
36. St Sauver JL, Jacobson DJ, McGree ME, et al. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006;164(8):760-768.
37. Drachenberg DE, Elgamal AA, Rowbotham R, et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 1999;41(2):127-133.
38. Rohrmann S, De Marzo AM, Smit E, et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62(1): 27-33. (Pubitemid 39614290)
39. St Sauver JL, Sarma AV, Jacobson DJ, et al. Associations between C-reactive protein and benign prostatic hyperplasia/ lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol. 2009;169(11):1281-1290.
40. Van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA. 1992;89(11):4845-4849.
41. Engelmann H, Aderka D, Rubinstein M, et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989;264(20):11974-11980.
42. Sutcliffe S, Rohrmann S, Giovannucci E, et al. Viral infections and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey. J Urol. 2007;178(5):2181-2185. (Pubitemid 47554436)
43. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996;7(3):231-240. (Pubitemid 27200307)
44. Vandenabeele P, Declercq W, Beyaert R, et al. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5(10):392-399.
45. Abrams P, D'Ancona C, Griffiths D, et al. Lower urinary tract symptom: etiology, patient assessment and predicting outcome from therapy. In: McConnell J, Abrams P, Denis L, et al, eds. Male Lower Urinary Tract Dysfunction- Evaluation and Management. Paris, France: Health Publications; 2005:69-142.
46. Gades NM, Jacobson DJ, Girman CJ, et al. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int. 2005;95(4):549-553.